Cargando…
Docking Studies of Methylthiomorpholin Phenols (LQM300 Series) with Angiotensin-Converting Enzyme (ACE)
A main target in the treatment of hypertension is the angiotensin-converting enzyme (ACE). This enzyme is responsible for producing angiotensin II, a potent vasoconstrictor. Therefore, one of the targets in the treatment of hypertension is to inhibit ACE activity. Hence, this study’s aim is to use c...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bentham Open
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3849751/ https://www.ncbi.nlm.nih.gov/pubmed/24319502 http://dx.doi.org/10.2174/1874104501307010030 |
_version_ | 1782293982046322688 |
---|---|
author | Vázquez-Valadez, Víctor H. Abrego, V.H. Martínez, Pablo A. Torres, Gabriela Zúñiga, Oscar Escutia, Daniel Vilchis, Rebeca Velázquez, Ana Ma. Martínez, Luisa Ruiz, Mónica Camacho, Brígida López-Castañares, Rafael Angeles, Enrique |
author_facet | Vázquez-Valadez, Víctor H. Abrego, V.H. Martínez, Pablo A. Torres, Gabriela Zúñiga, Oscar Escutia, Daniel Vilchis, Rebeca Velázquez, Ana Ma. Martínez, Luisa Ruiz, Mónica Camacho, Brígida López-Castañares, Rafael Angeles, Enrique |
author_sort | Vázquez-Valadez, Víctor H. |
collection | PubMed |
description | A main target in the treatment of hypertension is the angiotensin-converting enzyme (ACE). This enzyme is responsible for producing angiotensin II, a potent vasoconstrictor. Therefore, one of the targets in the treatment of hypertension is to inhibit ACE activity. Hence, this study’s aim is to use computational studies to demonstrate that the proposed heterocyclic compounds have a molecular affinity for ACE and that, furthermore, these heterocyclic compounds are capable of inhibiting ACE activity, thus avoiding the production of the vasopressor Angiotensin II. All this using computer-aided drug design, and studying the systems, with the proposed compounds, through molecular recognition process and compared with the compounds already on the market for hypertension. |
format | Online Article Text |
id | pubmed-3849751 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Bentham Open |
record_format | MEDLINE/PubMed |
spelling | pubmed-38497512013-12-06 Docking Studies of Methylthiomorpholin Phenols (LQM300 Series) with Angiotensin-Converting Enzyme (ACE) Vázquez-Valadez, Víctor H. Abrego, V.H. Martínez, Pablo A. Torres, Gabriela Zúñiga, Oscar Escutia, Daniel Vilchis, Rebeca Velázquez, Ana Ma. Martínez, Luisa Ruiz, Mónica Camacho, Brígida López-Castañares, Rafael Angeles, Enrique Open Med Chem J Article A main target in the treatment of hypertension is the angiotensin-converting enzyme (ACE). This enzyme is responsible for producing angiotensin II, a potent vasoconstrictor. Therefore, one of the targets in the treatment of hypertension is to inhibit ACE activity. Hence, this study’s aim is to use computational studies to demonstrate that the proposed heterocyclic compounds have a molecular affinity for ACE and that, furthermore, these heterocyclic compounds are capable of inhibiting ACE activity, thus avoiding the production of the vasopressor Angiotensin II. All this using computer-aided drug design, and studying the systems, with the proposed compounds, through molecular recognition process and compared with the compounds already on the market for hypertension. Bentham Open 2013-11-23 /pmc/articles/PMC3849751/ /pubmed/24319502 http://dx.doi.org/10.2174/1874104501307010030 Text en © Vázquez-Valadez et al.; Licensee Bentham Open. http://creativecommons.org/licenses/by-nc/3.0/ This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited. |
spellingShingle | Article Vázquez-Valadez, Víctor H. Abrego, V.H. Martínez, Pablo A. Torres, Gabriela Zúñiga, Oscar Escutia, Daniel Vilchis, Rebeca Velázquez, Ana Ma. Martínez, Luisa Ruiz, Mónica Camacho, Brígida López-Castañares, Rafael Angeles, Enrique Docking Studies of Methylthiomorpholin Phenols (LQM300 Series) with Angiotensin-Converting Enzyme (ACE) |
title | Docking Studies of Methylthiomorpholin Phenols (LQM300 Series) with Angiotensin-Converting Enzyme (ACE) |
title_full | Docking Studies of Methylthiomorpholin Phenols (LQM300 Series) with Angiotensin-Converting Enzyme (ACE) |
title_fullStr | Docking Studies of Methylthiomorpholin Phenols (LQM300 Series) with Angiotensin-Converting Enzyme (ACE) |
title_full_unstemmed | Docking Studies of Methylthiomorpholin Phenols (LQM300 Series) with Angiotensin-Converting Enzyme (ACE) |
title_short | Docking Studies of Methylthiomorpholin Phenols (LQM300 Series) with Angiotensin-Converting Enzyme (ACE) |
title_sort | docking studies of methylthiomorpholin phenols (lqm300 series) with angiotensin-converting enzyme (ace) |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3849751/ https://www.ncbi.nlm.nih.gov/pubmed/24319502 http://dx.doi.org/10.2174/1874104501307010030 |
work_keys_str_mv | AT vazquezvaladezvictorh dockingstudiesofmethylthiomorpholinphenolslqm300serieswithangiotensinconvertingenzymeace AT abregovh dockingstudiesofmethylthiomorpholinphenolslqm300serieswithangiotensinconvertingenzymeace AT martinezpabloa dockingstudiesofmethylthiomorpholinphenolslqm300serieswithangiotensinconvertingenzymeace AT torresgabriela dockingstudiesofmethylthiomorpholinphenolslqm300serieswithangiotensinconvertingenzymeace AT zunigaoscar dockingstudiesofmethylthiomorpholinphenolslqm300serieswithangiotensinconvertingenzymeace AT escutiadaniel dockingstudiesofmethylthiomorpholinphenolslqm300serieswithangiotensinconvertingenzymeace AT vilchisrebeca dockingstudiesofmethylthiomorpholinphenolslqm300serieswithangiotensinconvertingenzymeace AT velazquezanama dockingstudiesofmethylthiomorpholinphenolslqm300serieswithangiotensinconvertingenzymeace AT martinezluisa dockingstudiesofmethylthiomorpholinphenolslqm300serieswithangiotensinconvertingenzymeace AT ruizmonica dockingstudiesofmethylthiomorpholinphenolslqm300serieswithangiotensinconvertingenzymeace AT camachobrigida dockingstudiesofmethylthiomorpholinphenolslqm300serieswithangiotensinconvertingenzymeace AT lopezcastanaresrafael dockingstudiesofmethylthiomorpholinphenolslqm300serieswithangiotensinconvertingenzymeace AT angelesenrique dockingstudiesofmethylthiomorpholinphenolslqm300serieswithangiotensinconvertingenzymeace |